Cargando…

Corrigendum to Inaba M, Une Y, Ikejiri K, et al. “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial.” Kidney Int Rep. 2022;7:177–188

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263200/ https://www.ncbi.nlm.nih.gov/pubmed/35812270 http://dx.doi.org/10.1016/j.ekir.2022.06.008

Ejemplares similares

Corrigendum to Gathmyr D, Maruhum Bonar M, Susilo A, Harimurti K. “The relationship between IL-6, IL-10, TNF-α with AKI in moderate and severe COVID-19 patients [abstract POS-014].” Kidney Int Rep. 2022;7(suppl 1):S6
Publicado: (2022)

The effects of tenapanor on serum fibroblast growth factor 23 in patients receiving hemodialysis with hyperphosphatemia
por: Block, Geoffrey A, et al.
Publicado: (2019)

Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial
por: Inaba, Masaaki, et al.
Publicado: (2021)

Randomized Study of Tenapanor Added to Phosphate Binders for Patients With Refractory Hyperphosphatemia
por: Nitta, Kosaku, et al.
Publicado: (2023)

Tenapanor as Add-on Treatment for Hyperphosphatemia in Dialysis Patients: Enough Bang for the Buck?
por: Wish, Jay B.
Publicado: (2023)

Corrigendum to “The Cumulative Rate of SARS-CoV-2 Infection in Chinese Hemodialysis Patients” [Kidney Int. Rep. 2020 1416–1421]
por: Xu, Xin, et al.
Publicado: (2021)

Letter Regarding “Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial”
por: Aoki, Yuki, et al.
Publicado: (2022)

In Reply to “Letter Regarding ‘Dose-Response of Tenapanor in Patients With Hyperphosphatemia Undergoing Hemodialysis in Japan—A Phase 2 Randomized Trial’”
por: Inaba, Masaaki, et al.
Publicado: (2022)

Long-term safety and decrease of pill burden by tenapanor therapy: a phase 3 open-label study in hemodialysis patients with hyperphosphatemia
por: Koiwa, Fumihiko, et al.
Publicado: (2023)

Tenapanor Improves Long-Term Control of Hyperphosphatemia in Patients Receiving Maintenance Dialysis: the NORMALIZE Study
por: Silva, Arnold L., et al.
Publicado: (2023)

Corrigendum to “Successful Urine Multiplex Bead Assay to Measure Lupus Nephritis Activity” Kidney Int. Rep. 2021;6:1949-1960.
por: Cody, Ellen M., et al.
Publicado: (2021)

Corrigendum to “Luyckx VA, Cherney DZI, Bello AK. Preventing CKD in Developed Countries.” Kidney Int Rep. 2020;5:263–277
Publicado: (2020)

Corrigendum to “Kimura T, Snijder R, Nozaki K. Diagnosis patterns of CKD and anemia in the Japanese population.” Kidney Int. Rep. 2020;5:694–705
Publicado: (2020)

Corrigendum to “Narita I. Estimating Growth Rate by a Single Measurement of Kidney Volume in ADPKD.” Kidney Int Rep. 2020;5:1383–1384
Publicado: (2021)

Corrigendum to “Endoscopic closure of persistent gastric leak and fistula following laparoscopic sleeve gastrectomy” [Int. J. Surg. Case Rep. 6 (2015) 186–187]
por: Luthra, Anjuli K., et al.
Publicado: (2016)

SAT-337 Acute kidney injury in patients with solid organ and haematological malignancies: a single centre experience. Kidney Int Rep. 2019;4:S149
Publicado: (2019)

Ganesh K, Nair RR, Kurian G, et al. Posterior reversible encephalopathy syndrome in kidney disease. Kidney Int Rep. 2018;3:502–507
Publicado: (2018)

Effect of Tenapanor on Phosphate Binder Pill Burden in Hemodialysis Patients
por: Akizawa, Tadao, et al.
Publicado: (2021)

Corrigendum to Shi M, Yu S, Ouyang Y, et al. Increased lifetime risk of ESRD in familial IgA nephropathy. Kidney Int Rep. 2021;6:91-100.
Publicado: (2021)

Ismail H, Abdul Manaf MR, Abdul Gafor AH, et al. Economic burden of ESRD to the Malaysian health care system. Kidney Int Rep. 2019;4:1261–1270
Publicado: (2019)

Afshinnia F, Rajendiran TM, Karnovsky A, et al. Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort. Kidney Int Rep. 2016;1:256–268
Publicado: (2017)

Corrigendum to “Morales-Alvarez MC, Garcia-Dolagaray G, Millan-Fierro A, Rosas SE. Renal function decline in Latinos with type 2 diabetes.” Kidney Int Rep. 2019;4:1230–1234
Publicado: (2020)

Evans M, Grams ME, Sang Y, et al., for the Chronic Kidney Disease Prognosis Consortium. Risk factors for prognosis in patients with severely decreased GFR. Kidney Int Rep. 2018;3:625–637
Publicado: (2018)

Corrigendum to Davies SJ, Zhao J, Morgenstern H, et al. Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysis—International Results from PDOPPS. Kidney Int Rep. 2021;6:313-324.
Publicado: (2021)

Corrigendum to “Tentative study on radial endobronchial ultrasonography evaluating airway wall thickness before and after bronchial thermoplasty” [Respir. Med. Case Rep. 36 (2022) 101571]
por: Yan, Shang, et al.
Publicado: (2022)

Meneghini M, Melilli E, Martorell J, et al. Combining sensitive crossmatch assays with donor/recipient human leukocyte antigen eplet matching predicts living-donor kidney transplant outcome. Kidney Int Rep. 2018;3:926–938
Publicado: (2019)

Corrigendum to “The effect of misoprostol on the removal of endometrial polyps: A pilot clinical trial” [Int J Reprod BioMed 2022; 20: 461-468]
por: Aflatoonian, Abbas, et al.
Publicado: (2023)

Hollinger A, Wittebole X, François B, et al. Proenkephalin A 119-159 (Penkid) is an early biomarker of septic acute kidney injury: the Kidney in Sepsis and Septic Shock (Kid-SSS) Study. Kidney Int Rep. 2018;3:1424–1433
Publicado: (2018)

Corrigendum to “Leveraging data analytics to understand the relationship between restaurants’ safety violations and COVID-19 transmission” [Int. J. Hosp. Manag. 104 (2022) 103241]
por: Huang, Arthur, et al.
Publicado: (2022)

Perrone RD, Mouksassi M-S, Romero K, et al. Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep. 2017;2:442–450
Publicado: (2018)

Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis
por: Vasantha, J., et al.
Publicado: (2011)

Corrigendum to “Exploring social movement concepts and actions in a knowledge uptake and sustainability context: A concept analysis” [Int J Nurs Sci 9/4 (2022) 411–421]
por: Grinspun, Doris, et al.
Publicado: (2023)

Corrigendum to “First case of chromoblastomycosis from Bangladesh” [Med. Mycol. Case Rep. 10 (2015) 1–3]
por: Brun, Sophie, et al.
Publicado: (2016)

Corrigendum to “Examining the effects of stress and psychological distress on smoking abstinence in cancer patients” [Prev. Med. Rep. 23 (2021) 101402]
por: Streck, Joanna M., et al.
Publicado: (2021)

Corrigendum “Imaging features of the lungs hydatid cyst disseminated into the brain and spleen”. [Radiol Case Rep 2019;14:903–5]
por: Yaghoobi, Mojtaba Hedayat, et al.
Publicado: (2023)

Corrigendum to “Correlation between clinical and laboratory parameters and early pregnancy loss in assisted reproductive technology cycles: A cross-sectional study” [Int J Reprod BioMed 2022; 20: 683-690]
por: Emami, Fatemeh, et al.
Publicado: (2022)

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients
por: Maruyama, Sonomi, et al.
Publicado: (2020)

Corrigendum to “Extracellular expression of alkaline phytase in Pichia pastoris: influence of signal peptides, promoters and growth medium” Biotechnol. Rep. 6 (2015), 112–118
por: Yang, Mimi, et al.
Publicado: (2015)

Corrigendum to “Combined surgical and interventional radiological treatment for biliary leakage following iatrogenic biliary obstruction” [Radiol Case Rep 13 (2018) 772–777]
por: Paladini, Andrea, et al.
Publicado: (2019)

Sevelamer carbonate in the treatment of hyperphosphatemia in patients with chronic kidney disease on hemodialysis
por: Savica, Vincenzo, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_nbrhjaa49fbi4k5uhiuarq3k12